Evidence map›Paper›PMID 42559282›Full record

ArticleTheranostics2026

Metabolic-Immune Reprogramming via CuZnS@BSA Nanoregulators to Overcome Resistance in Triple-Negative Breast Cancer.

Jingyi Yang, Qi Li, Pi Zhao, Zixin Luo, Zhaokai Wang, Rui Yang, Min Zhou, Jie Zhou, Daozhen Chen, Yu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingyi YangAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Qi LiAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Pi ZhaoWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
Zixin LuoWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
Zhaokai WangWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
Rui YangAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Min ZhouAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Jie ZhouAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Daozhen ChenAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.
Yu ChenAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Since the therapeutic resistance of triple-negative breast cancer (TNBC) is mainly attributable to excessive glutathione (GSH) accumulation and its 'cold' immune landscape, we designed biomimetic CuZnS@BSA nanoregulators that exploit a pH-triggered 'disarm-and-attack' cascade, thereby initiating a well-defined, sequential therapeutic process in the acidic tumor microenvironment. Methods: Biomimetic CuZnS@BSA nanoclusters were synthesized via a self-assembly method. Their pH-responsive release kinetics and synergistic therapeutic mechanisms (GSH depletion, ROS generation, and cuproptosis) were systematically evaluated Results: The platform first releases H Conclusion: Combining this nanoregulator with PD-L1 blockade led to potent suppression of both subcutaneous tumor growth and lung metastasis, thus providing a direct, elegant link between metabolic reprogramming and systemic immune activation for TNBC therapy.

Indexed as

CopperDrug Resistance, NeoplasmTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorcGAS-STING Signaling PathwayCuproptosisFemaleGlutathioneHumansMetabolic ReprogrammingMiceMice, Inbred BALB CNanoparticlesSTING ProteinCopperGlutathioneSting1 protein, mouseSTING ProteinSulfidesZinccancer immunotherapycuproptosisimmunogenic cell deathstimulator of interferon genes (STING)triple-negative breast cancer

Identifiers

PMID42559282
PMCPMC13440635

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.